Recursion Pharmaceuticals (RXRX) Return on Sales (2020 - 2026)

Recursion Pharmaceuticals has reported Return on Sales for 7 years, with the latest figure at 0.18% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales fell 4.0% year-over-year to 0.18%; the trailing twelve-month figure through Mar 2026 stood at 0.08% (up 1.0% YoY), and the FY2025 full-year result was 0.09%, down 1.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.18%, down from 0.03% in the prior quarter.
• The five-year high for Return on Sales was 0.03% in Q4 2025, with the low at 0.39% in Q4 2024.
• Historically, Return on Sales has averaged 0.11% across 5 years, with a median of 0.09% in 2023.
• Annual changes were most pronounced in 2024 — Return on Sales sank 31 bps — and 2025, when it jumped 36 bps.
• Recursion Pharmaceuticals' Return on Sales stood at 0.04% in 2022, then sank by 91 bps to 0.09% in 2023, then tumbled by 361 bps to 0.39% in 2024, then jumped by 92 bps to 0.03% in 2025, then plunged by 497 bps to 0.18% in 2026.
• The last three Return on Sales figures came in at 0.18% (Q1 2026), 0.03% (Q4 2025), and 0.31% (Q3 2025), per Business Quant data.